Malaria attributable fevers (MAF)/febrile patients (dry season)
|
1.7%
|
Primary
|
Malaria attributable fevers (MAF)/febrile patients (rainy season)
|
25.1%
|
Primary
|
Malaria parasite density > 40,000/μL (both seasons)
|
36.8%
|
Primary
|
Death rate treated MAF, high parasite density
|
0.0%
|
Primary
|
Excess death rate untreated MAF, high parasite density
|
0.4%
|
Assumption
|
Excess death rate untreated MAF low parasite density
|
0.0%
|
Assumption
|
Excess death rate untreated MAF in RDT neg
|
0.0%
|
Assumption
|
Death rate treated NMFI
|
0.84%
|
Primary
|
Proportion of potentially fatal non malarial fever (PFNM)
|
20%
|
Assumption
|
Excess death rate untreated PFNM
|
7%
|
Assumption
|
CASE MANAGEMENT, PRESUMPTIVE BRANCH, ADULTS
| | |
Anti-malarial treatment among MAF
|
97%
|
Primary
|
Anti-malarial treatment among MAF, high parasite density
|
97.3%
|
Primary
|
Anti-malarial treatment among MAF, low parasite density
|
97%
|
Assumption
|
Anti-malarial treatment among those treated with antibiotics
|
79.3%
|
Primary
|
Anti-malarial treatment among those not treated with antibiotics
|
94.8%
|
Primary
|
Antibiotic treatment among NMFI
|
56.1%
|
Primary
|
Antibiotic treatment among PFMN
|
90%
|
Assumption
|
Antibiotic treatment among patients presumptively treated for malaria
|
47.1%
|
Primary
|
Antibiotic treatment among PFMN presumptively treated for malaria
|
86%
|
Assumption
|
Antibiotic treatment among patients not presumptively treated for malaria
|
80.8%
|
Primary
|
Antibiotic treatment among PFMN not treated for malaria
|
99%
|
Assumption
|
CASE MANAGEMENT, RDT, ADULTS
| | |
Anti-malarial treatment among RDT+, high parasite density (hpd)
|
100%
|
Primary
|
Anti-malarial treatment among RDT+, low parasite density (lpd)
|
96.4%
|
Primary
|
Anti-malarial treatment among RDT-
|
10%
|
Assumption
|
Antibiotic treatment among RDT+
|
42.5%
|
Primary
|
Antibiotic treatment among PFNM RDT+
|
86%
|
Assumption
|
Antibiotic treatment among RDT-
|
77.4%
|
Assumption
|
Antibiotic treatment among PFNM RDT-
|
98.6%
|
Assumption
|
RDT ACCURACY, ADULTS
| | |
RDT sensitivity, malaria attributable fever (MAF), lpd, dry season
|
91.6%
|
Primary
|
RDT specificity, malaria attributable fever (MAF), dry season
|
78.7%
|
Primary
|
RDT sensitivity, malaria attributable fever (MAF), lpd, rainy season
|
95.3%
|
Primary
|
RDT specificity, malaria attributable fever (MAF), rainy season
|
77.4%
|
Primary
|
RDT sensitivity, MAF, high parasite density
|
99%
|
Primary
|
COSTS, ADULTS
| | |
Cost of RDT
|
0.71
|
(ref. 26)
|
Cost of anti-malarial treatment, Coartem (average, €)
|
2
|
(ref. 26)
|
Cost of antibiotic treatment (average, €)
|
0.4
|
Estimate
|
Life Value (€) corresponding to 25 US $*YLL
|
525
|
(see text)
|
Life Value (€) corresponding to 150 US $*YLL
|
3150
|
(see text)
|